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The Clinical Significance of Occult Gastrointestinal Primary Tumours in
Metastatic Cancer: A Population Retrospective Cohort Study

Purpose
The purpose of this study was to estimate the incidence of occult gastrointestinal (GI) primary tumours in patients with metastatic cancer of uncertain primary origin and evaluate
their influence on treatments and overall survival (OS).
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Materials and Methods
We used population heath data from Manitoba, Canada to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011. We defined patients to have “occult”
primary tumour if the primary was found at least 6 months after initial diagnosis. Otherwise,
we considered primary tumours as “obvious.” We used propensity-score methods to match
each patient with occult GI tumour to four patients with obvious GI tumour on all known clinicopathologic features. We compared treatments and 2-year survival data between the two
patient groups and assessed treatment effect on OS using Cox regression adjustment.
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Results
Eighty-three patients had occult GI primary tumours, accounting for 17.6% of men and 14%
of women with metastatic cancer of uncertain primary. A 1:4 matching created a matched
group of 332 patients with obvious GI primary tumour. Occult cases compared to the
matched group were less likely to receive surgical interventions and targeted biological therapy, and more likely to receive cytotoxic empiric chemotherapeutic agents. Having an occult
GI tumour was associated with reduced OS and appeared to be a nonsignificant independent predictor of OS when adjusting for treatment differences.
Conclusion
GI tumours are the most common occult primary tumours in men and the second most
common in women. Patients with occult GI primary tumours are potentially being undertreated with available GI site-specific and targeted therapies.
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Introduction

Materials and Methods

According to the Canadian Cancer Society, gastrointestinal
(GI) cancer is the most common type of cancer and cause of
cancer death in Canada [1]. In 2016, 46,000 Canadians will be
diagnosed with cancers of the GI tract involving the esophagus, stomach, biliary system, pancreas, small intestine, colon,
rectum, and anus and 22,000 Canadians will die from these
cancers [1]. The tendency of GI cancers to be either asymptomatic at early stages or to present with vague symptoms
that might be mistaken for other inflammatory diseases at
more advanced stages, as well as the lack of accurate screening procedures for many of these cancers, contribute to the
diagnosis of GI cancers at more advanced-stages, often after
they metastasize to other areas of the body [2].
Patients with metastatic cancers of the GI tract may have
clinical and pathologic presentation masking their actual GI
tract origin (i.e., occult GI tumour). A series of recent analyses
of gene profiling molecular assays predicted the GI tract to
be the most common cancer site of origin in patients initially
diagnosed with metastatic cancer of unknown origin,
accounting for 34% to 45% of these patients [3-5]. In a small
number of case reports, metastatic disease of occult GI primary tumours have also been shown to have clinicopathologic features that mimic metastatic disease from other
cancer sites of origin leading to a diagnostic and thus treatment conundrum [6-14]. It is essential to correctly distinguish
a GI primary site from metastatic disease of other primary
sites not only for selection of a growing arsenal of effective
first-line site-specific or targeted therapies which may
improve survival [15], but also for the selection of secondline chemotherapy, decisions regarding debulking surgery
or surgery for resection of metastases, optimal management
of symptoms, prognosis, and recommendations regarding
entry into hospice care.
Currently, little is known about the clinical significance of
metastatic disease of occult GI primary tumours in actual
clinical practice. In this study, we used provincial heath
administrative databases in the Canadian province of Manitoba to identify occult GI primary tumours in patients with
metastatic cancer of uncertain primary (i.e., difficult to diagnose primary) and estimate their actual incidence. We also
aimed to compare those patients to their counterparts of
patients with metastatic disease of obvious (i.e. readily diagnosed) GI primary tumours to evaluate the impact of having
an occult GI primary tumour on disease management and
overall survival.

1. Data sources and identification of study population
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We conducted a retrospective cohort study using administrative health data obtained by linking the databases of the
Manitoba Cancer Registry (MCR) and Provincial Pharmacy
program of CancerCare Manitoba (CCMB) with Manitoba
Health’s administrative databases, including the Hospital
Discharge Database, Physician Claims Database and the
Drug Program Information Network (DPIN). A full description of these databases, their contents and the linkage process
has been reported elsewhere [16-19].
We used the MCR to identify all metastatic cancer patients
(defined as stage IV or distant metastasis within 4 months of
initial diagnosis) during the period from January 1, 2002, to
December 31, 2011. All Manitoba residents aged 18 to 90
years old with no history of cancer at diagnosis who had
their metastatic disease histologically confirmed and survived at least 6 months following their initial cancer diagnosis were eligible for inclusion in our metastatic patient
population. This 6-month window was important to ensure
that patients would have had reasonable survival time during the early course of their metastatic disease to undergo a
full diagnostic workup and have their primary tumour site
identified [20]. When the primary tumour was identified 6
months or more after initial diagnosis, we defined patients
to have “occult” primary tumour (i.e., metastatic cancer of
uncertain primary). Otherwise, we defined patients to have
“obvious” primary tumour. Our case definition is consistent
with other attempts at identifying occult primary tumours
[20]. Full details regarding the identification of our metastatic
patient population are reported elsewhere [21].
For this analysis, we used our metastatic patient population to identify all patients diagnosed with metastatic cancer
of GI sites including esophagus, gastroesophageal junction,
stomach, small intestine, colon, rectum, anus, anal canal,
liver, intra hepatic bile duct, extra hepatic bile duct, gallbladder, pancreas, and other unspecified GI tract. We stratified
this group into two main subgroups: (1) patients with occult
GI tumours and (2) patients with obvious GI tumours. Twoyear follow-up information was collected from the MCR for
each patient in the two subgroups including surgical and
therapeutic radiology procedures, systemic therapies, palliative care, diagnosis of second primary and death.
We linked those patients with the Provincial Pharmacy
Program of CCMB and Manitoba Health’s administrative
databases to validate all cancer therapy data captured by the
MCR; to collect additional information on types of radiotherapy, chemotherapy, and targeted cancer therapy agents as
described elsewhere [16-19]; and to measure co-morbidity
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using the method developed by Charlson et al. [22] and used
elsewhere [18,19,21]. We also used, in particular, the Physician Claims Database to collect information on GI diagnostic
examinations received during the diagnostic workup (defined as the period from 6 months before to 6 months after cancer diagnosis) for all identified patients diagnosed with
metastatic cancer of GI sites. The GI diagnostic examinations
recorded in the Physician Claims Database included diagnostic laparoscopy or laparotomy, diagnostic GI endoscopic
examinations (i.e., esophagoscopy and esophagogastroduodenoscopy, gastroscopy, enteroscopy, endoscopic ultrasound, colonoscopy, and proctosigmoidoscopy), taking of
biopsy from a GI site, abdominal ultrasound, computerized
axial tomography (CT) scan of the abdomen, magnetic resonance imaging (MRI) scan of the abdomen, and GI nuclear
scans.
Ethics approval for the study was obtained from the University of Manitoba Health Research Ethics Board, Manitoba
Health Information Privacy Committee and University of
Western Ontario Health Research Ethics Board.
2. Statistical analysis
Continuous data are reported as mean±standard deviation, and categorical data, as numbers and percentages. Categorical data were compared using the chi-square test.
Quantitative variables were compared using the t test. All
statistical tests were two-sided and results were considered
significant at the 5% critical level. Statistical analysis was performed using SAS ver. 9.3 (SAS Institute Inc., Cary, NC).
We performed a matched analysis within our cohort study.
We used logistic regression to create a propensity score (i.e.,
likelihood) [23] for having occult GI primary tumour, using
the following potential confounders, which were available
for the entire cohort: age, sex, Charlson co-morbidity score,
number and type of metastatic sites, grade differentiation,
primary tumour site, histology, and year of initial diagnosis,
regardless of their individual statistical significance. We used
the propensity score to match each patient who had an occult
GI tumour with up to four patients who had obvious GI
tumour on the estimated propensity score. To avoid a poor
quality match, we only considered observations that were
within a ±0.01 of the occult unit’s propensity score for matching and chose the closest match without replacement (i.e.,
caliper matching without replacement) [23]. When no
matches were found that case would be dropped.
Time to death was assessed using Kaplan-Meier survival
curves. The curves were compared using the log-rank test
statistic. Cox proportional hazard modeling was used to calculate hazard ratios (HRs) with associated 95% confidence
intervals (CIs) to assess the differences between occult cases
and the matched group with respect to 2-year overall sur-

vival (OS). We tested the effect of cancer treatments on the
calculated HR for cases with occult versus matched patients
with obvious GI primary tumours. We included receipt of
surgical resection (no vs. yes), radiotherapy (no vs. yes), and
systemic therapy (i.e., chemotherapy or biological targeted
therapy) (no vs. yes) as covariates in a Cox proportional hazard model. We also tested the interactions between these
covariates and status of primary tumour (occult vs. obvious
GI tumour). In subgroup analyses in which we included
patients from the case and matched groups who were treated
with a given cancer therapy, we examined the effect of wait
time after initial diagnosis to receive that cancer treatment
and the effect of receipt of certain type of therapeutic agents
versus others on OS.
In separate analyses we used Kaplan-Meier survival
curves and Cox regression to compare the 2-year OS in the
case group of patients with occult GI tumours to all patients
with obvious GI primary tumours and generate HR. We conducted standard adjusted analyses by including all potential
confounders mentioned earlier in this section as covariates
in a Cox proportional hazard model. We also used the
propensity score to adjust for differences in baseline characteristics between the two patient groups using two methods.
First, we used the propensity score as a covariate in a Cox
proportional hazard model and generate adjusted HR [23].
Second, we used a weighted Cox proportional hazards
model and generate adjusted HR, where the weight assigned
for each patient was based on the stabilized inverse propensity score as previously described [24].

Results
There were 529 patients who had metastatic cancer of
uncertain primary origin (i.e., had an occult primary tumour),
accounting for 8.9% of all patients newly diagnosed with
metastatic cancer who met the inclusion criteria (n=5,953)
(Table 1). Of those, there were 83 patients with occult GI primary tumour, accounting for 15.7% of all patients with
metastatic cancer of uncertain primary and 5% of all patients
with metastatic GI primary tumour (n=1,656) (Table 1).
Prior to matching, patients with metastatic cancer of occult
GI primary tumours presented with distinctive clinicopathologic features from their counterparts of all patients with
obvious GI primary tumours (n=1,573) (Table 2). Using 1:4
matching on the estimated propensity score, we matched the
case group of 83 patients with occult GI primary tumours with
a group of 332 patients with obvious GI primary tumours. No
occult cases were dropped due to poor match quality. Table 2
shows the baseline patient and tumour characteristics of the
VOLUME 50 NUMBER 1 JANUARY 2018
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Table 1. Primary tumour site of 5,953 patients diagnosed with metastatic cancer by sex and diagnostic status of primary
tumour

Primary tumour site

Gastrointestinal tumours
Lung and pleural tumours
Urological tumours
Lymphoma tumours
Head and neck tumours
Gynecologic tumours
Breast tumours
Unknown primary tumour site
(primary tumour never diagnosed)
Melanoma (skin) tumours
Bone and soft tissue sarcoma tumours
Endocrine tumours
Ophthalmic tumours
Ill-defined tumours
Brain tumours

Patients with obvious
primary tumour
Men
(n=3,157)

Women
(n=2,267)

960 (30.4)
607 (19.2)
910 (28.8)
266 (8.4)
279 (8.8)
1 (< 0.1)
-

613 (27.0) 1,573 (29.0)
604 (26.6) 1,211 (22.3)
89 (3.9)
999 (18.4)
211 (9.3)
477 (8.8)
91 (4.0)
370 (6.8)
265 (11.7)
265 (4.9)
280 (12.4)
281 (5.2)
-

57 (1.8)
35 (1.1)
38 (1.2)
2 (< 0.1)
1 (< 0.1)
1 (< 0.1)

25 (1.1)
41 (1.8)
44 (1.9)
4 (0.2)
0(
0(

All
(n=5,424)

82 (1.5)
76 (1.4)
82 (1.5)
6 (0.1)
1 (< 0.1)
1 (< 0.1)

Patients with occult
primary tumour
Men
(n=244)

Women
(n=285)

All
(n=529)

43 (17.6) 40 (14.0) 83 (15.7)
21 (8.6)
21 (7.4)
42 (7.9)
39 (16)
6 (2.1)
45 (8.5)
10 (4.1)
10 (3.5)
20 (3.8)
18 (7.4)
3 (1.1)
21 (4.0)
55 (19.3) 55 (10.4)
0(
4 (1.4)
4 (0.7)
99 (40.6) 129 (45.2) 228 (43.1)
6 (2.4)
6 (2.4)
2 (0.8)
0(
0(
0(

6 (2.1)
6 (2.1)
4 (1.4)
0(
1(
0(

12 (2.3)
12 (2.3)
6 (1.1)
0(
1 (0.2)
0(

All patients
diagnosed with
metastatic
cancer (n=5,953)
1,656 (27.8)
1,253 (21.0)
1,044 (17.5)
497 (8.3)
391 (6.6)
320 (5.4)
285 (4.8)
228 (3.8)
94 (1.6)
88 (1.5)
88 (1.5)
6 (0.1)
2 (< 0.1)
1 (< 0.1)

Values are presented as number (%).

matched group (n=332) as compared to the case group of 83
patients with occult GI primary tumours. As a result of matching, we eliminated differences in age, sex, year of initial diagnosis, co-morbidity score, grade differentiation, GI primary
tumour location, histology, and number and type of metastatic
sites between occult cases and the matched group (Table 2).
Compared to the matched group, occult cases experienced on
average a longer time of 10.8 months after initial cancer diagnosis to have their primary tumour identified (Table 2). During the diagnostic workup, occult cases compared to the
matched group received similar diagnostic laparoscopies or
laparotomies and abdominal diagnostic imaging examinations. However, occult cases were less likely to receive any
type of diagnostic GI endoscopic examinations (mean difference, 33.4%; 95% CI, 21.8 to 45; p < 0.001) including upper GI
endoscopy (mean difference, 14.5%; 95% CI, 4.5 to 24.9;
p=0.01), lower GI endoscopy (mean difference, 14.2%; 95% CI,
2.8 to 25.5; p=0.01), endoscopic ultrasound (mean difference,
15%; 95% CI, 10.5 to 19.7; p < 0.001), and endoscopic retrograde cholangio-pancreatography (mean difference, 13%; 95%
CI, 7.9 to 18; p < 0.001) (Table 2).
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1. Treatment characteristics
Receipt of systemic therapy and time to radiotherapy and
systemic therapy after initial diagnosis did not differ significantly between the occult cases and matched group (Table 3).
Occult cases compared to matched patients were less likely to
have surgical resections (mean difference, 20.2%; 95% CI, 8.5
to 31.8; p=0.001) and receive radiotherapy (mean difference,
15.7%; 95% CI, 6 to 25.3; p=0.005) (Table 3). Among all patients
who had surgical resections, the time to surgery was longer
for cases compared to matched patients (mean difference, 1
month; 95% CI, 0.17 to 1.85; p=0.01) (Table 3). Among all
patients who received systemic therapy, cases were more
likely to receive platinum drugs (mean difference, 20.7%; 95%
CI, 5.3 to 36.1; p=0.01), anthracyclines (mean difference, 15.7%;
95% CI, 3.4 to 28.1; p=0.002) and taxanes (mean difference,
8.9%; 95% CI, 3 to 18.5; p=0.01) and less likely to receive biological targeted therapy (mean difference, 18%; 95% CI, 8.7 to
27.3; p=0.005) than matched patients (Table 3). Among
patients who received biological targeted therapy, cases were
more likely to receive bevacizumab (mean difference, 16%;
95% CI, 6.8 to 25.2; p=0.01) compared to the matched group
(Table 3). Table 3 shows the treatment characteristics of cases,
matched group with obvious GI tumours and all patients with
obvious GI tumours (n=1,573).
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Table 2. Baseline patient and tumour characteristics of 1,656 patients diagnosed with metastatic GI cancer by diagnostic
status of their primary tumours

Characteristic

Age at initial diagnosis (yr)
Mean±SD (range)
Year of initial diagnosis
2002-2003
2004-2005
2006-2007
2008-2009
2010-2011
Type of GI diagnostic examination
received during the diagnostic workupd)
Diagnostic laparoscopy or laparotomy
Upper GI endoscopy
Lower GI endoscopy
Endoscopic retrograde
cholangio-pancreatography
Endoscopic ultrasound
Any type of GI diagnostic
endoscopic exanimation
Taking of biopsy from a GI site
Abdominal ultrasound
CT scan of the abdomen
MRI scan of the abdomen
GI nuclear scan
Sex
Men
Women
GI primary tumour site
Esophagus and gastroesophageal junction
Stomach
Small intestine
Colon, rectum, anus, and anal canal
Liver and intrahepatic bile duct
Gallbladder
Extrahepatic bile duct
Pancreas
Unspecified GI tract
Grade differentiation
Well differentiated moderately
Moderately differentiated
Poorly differentiated
Undifferentiated
Histology
Adenocarcinomas
Cystic, mucinous and serous
Squamous, other epithelial,
unspecified epithelial, other non-epithelial
and undifferentiated

Patients with
obvious GI
primary
tumours (n=1,573)

Patients with
occult GI
primary
tumours (n=83)

64±12.5 (19-90)

62±11.7 (36-90)

p-valuea)

Matched patients
with obvious GI
primary tumours
(n=332)b)

p-valuec)

0.18

62±10.9 (35-90)

0.90

57 (17.2)
50 (15.06)
68 (20.5)
84 (25.3)
73 (21.98)

0.90

269 (17.1)
299 (19.0)
360 (22.9)
332 (21.1)
313 (19.9)

14 (16.9)
12 (14.5)
16 (19.3)
22 (26.5)
19 (22.9)

0.60

104 (6.6)
488 (31.02)
989 (62.9)
93 (5.9)

10 (12.04)
19 (22.9)
26 (31.3)
2 (2.4)

0.05
0.10
< 0.001
0.10

32 (9.6)
124 (37.3)
151 (45.5)
51 (15.4)

138 (8.8)
1,286 (81.7)

1 (1.2)
37 (44.6)

0.01
< 0.001

54 (16.3)
259 (78.01)

< 0.001
< 0.001

609 (38.7)
415 (26.4)
1,275 (81.05)
283 (17.99)
2 (0.12)

17 (20.5)
34 (40.96)
71 (85.5)
14 (16.9)
0(

< 0.001
0.003
0.30
0.80
> 0.99

86 (25.9)
118 (35.5)
264 (79.5)
67 (20.2)
1 (0.3)

0.30
0.30
0.20
0.50
> 0.99

960 (61.02)
613 (38.97)

43 (51.8)
40 (48.2)

0.09

175 (52.7)
157 (47.3)

0.90

159 (10.1)
96 (6.1)
31 (1.97)
1,101 (69.99)
23 (1.46)
18 (1.1)
16 (1.01)
127 (8.07)
2 (0.13)

9 (10.8)
4 (4.8)
6 (7.2)
35 (42.2)
3 (3.6)
2 (2.4)
7 (8.4)
15 (18)
2 (2.4)

< 0.001

38 (11.4)
16 (4.8)
26 (7.8)
140 (42.2)
14 (4.2)
8 (2.4)
25 (7.5)
63 (18.9)
2 (0.6)

0.90

65 (4.1)
826 (52.5)
296 (18.8)
386 (24.6)

6 (7.2)
18 (21.7)
18 (21.7)
41 (49.4)

< 0.001

24 (7.2)
73 (21.9)
73 (21.9)
162 (48.8)

0.90

1,307 (83.08)
121 (7.69)
145 (9.2)

57 (68.6)
13 (15.7)
13 (15.7)

0.003

225 (67.8)
55 (16.5)
52 (15.6)

0.90

0.50
0.01
0.01
0.001
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Table 2. Continued
Characteristic

Time interval between initial
cancer diagnosis and identification
of primary tumour (mo)
Mean±SD (range)
No. of patients (%)
" 0 to < 3
" 3 to < 6
" 6 to < 9
" 9 to < 12
" 12 to < 15
" 15 to < 24
No. of metastatic sites
1
2
3
"4
Metastatic sites
Digestive system
Respiratory system
Female genital system
Bones and joints
Lymph nodes
Buccal cavity and pharynx,
male genital system,
urinary system, brain, endocrine,
soft tissue (including heart), skin,
hematopoietic and reticuloendothelial
systems, others and ill-defined
With second primary tumour
Charlson co-morbidity scoree)
Mean±SD (range)
Score > 0
0
1
"2

Patients with
obvious GI
primary
tumours (n=1,573)

0.24±0.95 (0-5.9)

Patients with
occult GI
primary
tumours (n=83)

11±4 (6.1-22.9)

p-valuea)

< 0.001

Matched patients
with obvious GI
primary tumours
(n=332)b)

p-valuec)

0.30±1 (0-5.8)

< 0.001

1,505 (95.7)
68 (4.3)
0(
0(
0(
0(

0(
0(
32 (38.6)
21 (25.3)
17 (20.5)
13 (15.6)

452 (28.7)
757 (48.4)
267 (16.9)
88 (5.6)

32 (38.5)
27 (32.5)
19 (22.8)
5 (6.02)

0.07

127 (38.2)
112 (33.7)
74 (22.2)
19 (5.7)

0.90

1,690 (39.9)
645 (15.2)
52 (1.2)
146 (3.5)
1,376 (32.5)
326 (7.7)

82 (38.3)
35 (16.3)
14 (6.5)
20 (9.3)
52 (24.3)
11 (5.1)

0.001

237 (38.9)
97 (15.9)
39 (6.4)
54 (8.9)
146 (24.0)
36 (5.9)

0.90

60 (3.8)
0.30±0.77 (0-11)
344 (21.9)
1,229
271
73

0(
0.21±0.58 (0-4)
14 (16.9)
69
12
2

313 (94.3)
19 (5.7)
0(
0(
0(
0(

0.07
0.30
0.30

0(
0.22±0.6 (0-4)
60 (18)
272
48
12

> 0.99
0.90
0.80

Values are presented as number (%) unless otherwise indicated. GI, gastrointestinal; SD, standard deviation; CT, computed
tomography; MRI, magnetic resonance imaging. a)Patients with occult (n=83) vs. all obvious (n=1,573) using Fisher exact or
chi-square, b)Patients were matched on the estimated propensity score, c)Patients with occult (n=83) vs. matched obvious
(n=1,573) using Fisher exact or chi-square, d)Diagnostic workup was defined as the period from 6 months before to 6 months
after metastatic cancer diagnosis, e)Co-morbid diagnoses were considered present if they were found during 1 year before
and 6 months after the initial diagnosis with cancer.
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Table 3. Treatments of 1,656 patients diagnosed with metastatic GI cancer by diagnostic status of their primary tumours
Characteristic

Patients with
obvious GI
primary
tumours (n=1,573)

With surgical resection
1,055 (67.4)
Time interval between initial cancer
diagnosis and surgical resection (mo)
Mean±SD (range)
1.2±2.2 (0-20.1)
" 0 to < 3
953 (
" 3 to < 6
60 (
" 6 to < 12
29 (
" 12 to < 24
11 (
With radiotherapy
468 (29.7)
Time interval between initial cancer diagnosis
and start of radiotherapy (mo)
Mean±SD (range)
6.1±5.6 (0-24)
" 0 to < 3
161 (
" 3 to < 6
147 (
" 6 to < 12
94 (
" 12 to < 24
66 (
Type of radiotherapy
Teletherapy
346 (73.9)
Other types
122 (26.1)
With systemic therapy
1,176 (74.8)
Time interval between initial cancer
diagnosis and start of systemic therapy (mo)
Mean±SD (range)
3.4±3 (0-23.6)
" 0 to < 3
693 (
" 3 to < 6
359 (
" 6 to < 12
89 (
" 12 to < 24
35 (
With information about systemic
876 (74.5)
therapy agents received
Frequency of systemic therapy
agents received
Single agents
130 (14.8)
Double agents
370 (42.3)
Triple agents or more
376 (42.9)
Type of chemotherapeutic agents received
Antimetabolitesd)
841 (96.0)
Topoisomerase inhibitorse)
490 (55.9)
Platinum drugsf)
537 (61.3)
Anthracyclinesg)
57 (6.5)
Taxanesh)
26 (2.9)
Others agentsi)
26 (2.9)
With biological targeted therapy
176 (20.1)
Type of biological targeted
therapy agents received
Bevacizumab
149 (17.0)
Cetuximab
18 (2.0)
Panitumumab
11(1.3)
Other targeted therapy
3 (0.3)

Patients with
occult GI
primary
tumours (n=83)
30 (36.0)

1.9±4.2 (0-20.5)
25 (
2(
2(
1(
15 (18.0)

6.4±5.1 (0.6-15)
5(
3(
5(
2(
11 (73.3)
4 (26.7)
59 (71.1)

3.5±4.5 (0-22.9)
41 (
10 (
4(
4(
46 (77.9)

p-valuea)

< 0.001

0.09

0.02

0.80

0.90
0.45

0.90

0.50

Matched patients
with obvious GI
primary tumours
(n=332)b)
187 (56.3)

0.8±1.6 (0-12.6)
175 (
8(
4(
0(
112 (33.7)

7.6±6.7 (0.3-24)
33 (
29 (
24 (
26 (
87 (70.6)
33 (29.4)
261 (78.6)

3.4±3.4 (0-23.6)
162 (
70 (
18 (
11 (
200 (76.6)

p-valuec)

0.001

0.01

0.005

0.50

0.90
0.10

0.90

0.80

10 (21.7)
17 (36.9)
19 (41.3)

0.40

55 (27.5)
77 (38.5)
68 (34.0)

0.60

44 (95.6)
24 (52.2)
30 (65.2)
10 (21.7)
5 (10.8)
1 (2.2)
3 (6.5)

0.90
0.60
0.60
0.004
0.01
0.90
0.02

190 (95.0)
91 (45.5)
89 (44.5)
12 (6.0)
4 (2.0)
5 (2.5)
49 (24.5)

0.90
0.40
0.01
0.002
0.01
0.90
0.005

3 (6.5)
1 (2.1)
0(
0(

0.06
0.90
0.90
0.90

45 (22.5)
8 (4.0)
3 (1.5)
0(

0.01
0.90
0.90

VOLUME 50 NUMBER 1 JANUARY 2018

189

Cancer Res Treat. 2018;50(1):183-194

Table 3. Continued
Characteristic

With support drugs received to
control side effects or conditions
associated with chemotherapy

Patients with
obvious GI
primary
tumours (n=1,573)
774 (88.4)

Patients with
occult GI
primary
tumours (n=83)
32 (69.6)

p-valuea)

< 0.001

Matched patients
with obvious GI
primary tumours
(n=332)b)
151 (75.5)

p-valuec)

0.40

Values are presented as number (%) unless otherwise indicated. GI, gastrointestinal; SD, standard deviation. a)Patients with
occult (n=83) vs. all obvious (n=1,573) using Fisher exact or chi-square, b)Patients were matched on the estimated propensity
score, c)Patients with occult (n=83) vs. matched obvious (n=332) using Fisher exact or chi-square, d)Antimetabolites included
capecitabine, gemcitabine, 5-fluorouracil, and raltitrexed, e)Topoisomerase inhibitors included etoposide and irinotecan, f)Platinum drugs included carboplatin, cisplatin, and oxaliplatin, g)Anthracyclines included doxorubicin and epirubicin, h)Taxanes
included paclitaxel and docetaxel, i)Other agents included dexamethasone, vincristine, streptozocin, cyclophosphamide, and
mitomycin.

2. Survival outcomes

100

Stratified log-rank test p < 0.01 at 2 years

90

190

CANCER RESEARCH AND TREATMENT

80
Overall survival (%)

Cases had worse OS compared to matched patients (2-year
OS, 30% vs. 41.3%, p=0.01; median OS, 14.2 months vs. 20.3
months, Fig. 1) (HR, 1.44; 95% CI, 1.1 to 1.9; p=0.01) (Table 4).
In a Cox proportional-hazard regression analysis, having an
occult compared to an obvious GI tumour became a nonsignificant independent predictor of OS when controlling for use of
surgery, radiation therapy and chemotherapy (Table 4). In this
analysis, receipt of surgical resection and chemotherapy were
significant independent predictors of OS (Table 4). No interactions between treatment and primary tumour status (occult
vs. obvious) were identified.
In subgroup analyses, the time from diagnosis to surgery
was a significant independent predictor of OS in patients
treated with surgery (HR for one month increase in wait time,
1.09; 95% CI, 1.04 to 1.16; p=0.01). The times from diagnosis to
receipt of radiation therapy and systemic therapy were not significant independent predictors of OS. Similarly, the type of
chemotherapeutic agents received (platinum, taxanes and
anthracyclines vs. other chemotherapeutic combinations) was
not an independent significant predictor of OS in patients
treated with chemotherapy. However, receipt of biological targeted therapy was associated with survival advantage in
patients treated with systematic therapy from the case and
matched group (HR, 0.5; 95% CI, 0.08 to 0.83; p=0.001).
Unadjusted and adjusted Cox proportional-hazard regression analyses that compared OS of the case group of 83
patients with occult GI primary tumours to all patients with
obvious GI primary tumours (n=1,573) revealed similar results
(Table 4, Fig. 1).

70
60

46%

50
40

41.3%

30

30.1%

20

Patients with occult GI primary tumours (58 deaths)
Matched patients with obvious GI primary tumours (195 deaths)
All patients with obvious GI primary tumours (849 deaths)

10
0

0

2

4

6

No. at risk
83
332
1,573

83
332
1,573

8

10 12 14 16 18 20 22 24
Time (mo)
46
231
1,173

31
181
910

25
137
724

Fig. 1. Overall survival analyses comparing patients with
occult gastrointestinal (GI) primary tumours to patients
with obvious GI primary tumours.

1.19
1.21

0.002
0.02

1.54 1.17-2.05
1.38 1.05-1.8
1.73 1.44-2.08 < 0.001

1.31

1.32

< 0.001

1.3-2.2

1.23

HR

1.68

0.01

p-value

1.1-1.94

95% CI

1.45

HR

Occult vs.
Obvious

0.96-1.46

0.9-1.57

0.99-1.73

1.05-1.7

0.92-1.66

95% CI

Occult vs.
Obvious

0.06

0.20

0.05

0.04

0.16

p-value

3.31

3.18

2.7

3.3

3.88

HR

< 0.001

< 0.001

< 0.001

p-value

2.91-3.77 < 0.001

2.78-3.64 < 0.001

2.3-3.1

2.8-3.7

2.97-5.1

95% CI

Receipt of
surgical resection
(no vs. yes)b)

0.93

0.99

0.95

1.02

0.94

HR

0.82-1.05

0.78-1.29

0.73-1.18

0.8-1.17

0.76-1.27

95% CI

0.09

0.60

0.60

0.60

0.50

p-value

Receipt of
radiation therapy
(no vs. yes)b)

Adjusted for receipt of surgical resection,
radiation therapy, and chemotherapy

1.48

1.58

1.38

1.60

1.39

HR

0.001

p-value

1.28-1.7

< 0.001

1.37-1.84 < 0.001

1.16-1.65 < 0.001

1.38-1.85 < 0.001

1.15-1.74

95% CI

Receipt of
chemotherapy
(no vs. yes)b)

HR, hazard ratio; CI, confidence interval; GI, gastrointestinal. a)We created time dependent covariates by creating interactions of the covariates and a function of survival time in the models to test proportionality. When time dependent covariates were not significant then covariates were considered proportional. The proportionality assumption was appropriate for all, b)We tested the interaction between receipt of a given treatment (no vs. yes) and status of primary tumour (occult vs. obvious)
for significance and found none, c)Patient and disease characteristics included age, sex, co-morbidity, number and type of metastatic sites, grade differentiation, histology, primary tumour site, year of initial diagnosis.

For cases and matched patients
with obvious GI tumours
(4:1 matching, n=415)
For cases and all patients
with obvious GI tumours
(n=1,656)
Unadjusted for patient and
disease characteristics
Adjusted for patient and
disease characteristicsc)
Adjusted for the estimated
propensity score
Adjusted for patient and
disease characteristicsc) using
inverse probability weighting

Proportional-hazard
modela)

Unadjusted for
treatment characteristic

Table 4. Adjusted and unadjusted HR for death and 95% CI
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Discussion
To our knowledge, the present study is the first to determine the incidence of metastatic cancer of occult GI primary
tumours through a population-based analysis. With GI cancers being the most frequent occult primary tumours identified in men and the second most frequent in women with
metastatic cancer of uncertain primary, oncologists should
maintain a high index of suspicion in GI origins of disease
when conducting clinical, surgical, pathological, and radiological evaluations of these patients. It is necessary to understand the natural history of GI cancers because the incidence,
prognosis, and recommended treatment of these tumours
vary with anatomical location and histological subtype.
The absence of accurate determination of GI primary
tumours early in the course of metastatic cancer appears to
be associated with fewer diagnostic GI endoscopic examinations during the diagnostic workup, less frequent surgical
intervention and use of biological targeted therapy such as
bevacizumab, longer time to surgical interventions and
greater use of empiric (i.e., broad-spectrum) and more toxic
chemotherapeutic drugs such as platinum drugs, taxanes
and anthracyclines. Less exposure to surgery and biological
targeted therapy and a longer time to receive surgery were
all independently associated with higher risk of death and
appeared to account for a large portion of the observed 45%
increase in risk of mortality for patients with occult GI
tumours. This association should be interpreted with caution
as it might also be due to unexplained differences in tumour
biology, disease burden and/or the functional status of
patients differing between cases and the matched group.
However, it is still reasonable to hypothesize that many
patients were rendered unsuitable for certain effective and
targeted cancer treatment and treated with more intensive
empiric cytotoxic chemotherapy for their metastatic disease
due to the uncertainty of primary tumour site. The implication is that with the growing availability of more effective
personalized treatments, it is important to determine GI primary tumour sites early in the course of metastatic disease
for timely use of the best systemic and local treatment to
optimize patients’ survival and quality of life. The current
Canadian clinical practice has not been influenced by the
recently emerged gene expression profiling assays to help
identify the primary tumour in metastatic cancer [4,25-27].
These techniques complement current traditional diagnostic
procedures (e.g., immunohistochemical analyses, endoscopies, CT scans, X-rays, MRI scans, etc.) when dealing with
diagnostic difficulties so that the primary tumour can be classified early in the course of metastatic disease [28,29].
A precision medicine approach can often be applied to the
treatment of metastatic GI cancers [15]. There are now 10
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biological targeted therapies for these cancers that have been
approved by the U.S. Food and Drug Administration for clinical use (e.g., cetuximab, panitumumab, and bevacizumab
for colorectal cancer, trastuzumab, and regorafenib for gastric and gastroesophageal cancer) and many others are in
various phases of development [15]. Generally, these targeted therapies are studied, approved, and reimbursed
solely within the context of an identified GI primary tumour
location. In addition, selection of these treatments is not only
dependent on the biologic characteristics of individual GI
tumour (e.g., KRAS mutation and anti-epidermal growth factor receptor status) but also on knowledge of GI primary
tumour sites to interpret mutation results. For instance,
knowledge of KRAS mutation status has quite different
implications depending on whether the primary site is lung
versus colon. Therefore, information about the GI primary
tumour location and its inherent biologic characteristics are
both necessary and complementary for patients to access
new personalized treatments of metastatic GI cancers.
Although this is a retrospective cohort study and our
results must be considered hypothesis generating, the incidence of occult GI primary tumours and their impact on therapeutic decision making and patient outcomes are unlikely
to be studied in prospective designed analyses. This is
because metastatic cancer of occult GI source by definition
cannot be identified a priori and the size of any prospective
investigation would be too large to be feasible and would
take several years to complete. Furthermore, the randomization of metastatic patients potentially considered to have
occult GI primary tumours to different treatment modalities
might not be considered ethical due to the existence of sitespecific therapies and the possibility other therapeutic strategies might be less effective. Our retrospective cohort study
is an example of an alternative approach. This study used
rigorous linkage of high quality population data from comprehensive heath administrative databases and yielded true
incidence rates of occult GI primary tumours. We have taken
special care to avoid sources of bias and confounding in our
study by conducting a matched cohort analysis where the
matched patient group with obvious GI tumours clearly had
the same underlying population as the cases with occult GI
tumours and were matched on all known patient and
tumour characteristics. In fact, the smaller number of patients
included in our matched cohort analysis compared to our
overall cohort permits future investigation of more detailed
and expensive risk factors of having an occult GI tumour. For
instance, important factors associated with diagnostic
workup obtained from detailed medical histories or biologic
markers such as specialist referrals and type and frequency
of immunohistochemistry tests (i.e., information not collected by the databases used for this study) become feasible
to investigate in order to understand the actual diagnostic
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barriers in patients with occult GI tumours.
In conclusion, GI tumours are the most common occult primary tumours detected in men and the second most common
detected in women presenting with metastatic cancer of
uncertain primary. Currently, patients with occult GI primary tumours are potentially being undertreated with available GI site-specific and targeted therapies. It may be
beneficial to determine the occult GI primary tumour site
early in the course of metastatic cancer to enable more effective therapies and improve survival outcomes.
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